Results 301 to 310 of about 214,460 (382)

From Disease Control to Disease Modification: The Atopic Dermatitis Disease Activity Index

open access: yes
Allergy, EarlyView.
Thomas Bieber   +3 more
wiley   +1 more source

Wildfires and Atopic Diseases: A Review

open access: yesAllergy, EarlyView.
ABSTRACT Wildfire smoke is a major environmental health threat that has increased in frequency and severity in recent years. A hazardous component of wildfire smoke is particulate matter ≤ 2.5 μm (PM2.5). There is evidence to suggest that exposure to wildfire PM2.5 may increase the risk of developing or exacerbating atopic diseases, such as asthma ...
Alex Ha, John R. Balmes, Maria L. Wei
wiley   +1 more source

Molecular IgE Reactivity Profiling With Micro‐Arrayed Allergens Reveals Distinct Interregional Patterns of Sensitization and a Hypoallergenic Region in Türkiye

open access: yesAllergy, EarlyView.
A prospective, systematic and cross‐sectional population study was performed involving 1000 adult subjects from five centers representing different climatic areas of Türkiye (Turkey). Molecular IgE profiling demonstrated substantial interregional variation and identified a hypoallergenic region in the easternmost area with a continental climate.
Alp Kazancioglu   +22 more
wiley   +1 more source

Clinical and Molecular Effect of the Anti–IL‐18 Antibody Aletekitug in Adults With Atopic Dermatitis

open access: yesAllergy, EarlyView.
At Week 12, aletekitug was associated with a −68.3% percentage change from baseline in EASI score. Aletekitug improved the transcriptional profile of lesional skin towards that of non‐lesional skin at Week 4 and Week 12. Aletekitug was well‐tolerated; no serious adverse event or death occurred, and no patient withdrew due to an adverse event.
Joanne Ellis   +32 more
wiley   +1 more source

Use of over-the-counter antiallergic products-analysis of sales data in Poland from 2020 to 2023. [PDF]

open access: yesFront Pharmacol
Dudziński Ł   +5 more
europepmc   +1 more source

Sleep quality after caesarean delivery: associated factors and effects on quality of life and early breastfeeding. [PDF]

open access: yesAnn Med
Jintadawong T   +4 more
europepmc   +1 more source

Long‐Term Efficacy and Safety of Ligelizumab as Re‐Treatment in Patients With Chronic Spontaneous Urticaria

open access: yesAllergy, EarlyView.
Ligelizumab re‐treatment in CSU patients showed sustained efficacy and tolerability. Over 50% achieved symptom control (UAS7 ≤ 6) by Week 12; benefits maintained through Week 52. No new safety signals observed; aligns with prior PEARL trial outcomes. CSU, chronic spontaneous urticaria; mg, milligram; q4w, every 4 weeks; UAS, urticaria activity score ...
Ana M. Gimenez‐Arnau   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy